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ABSTRACT  1 
The role of serum uric acid as a predictor of stroke remained controversial among general 2 
Japanese population. We conducted a prospective cohort study of 5235 men and 8185 women 3 
residents aged 40–79 years at baseline between 1985 and 1994, initially free from stroke, 4 
coronary heart disease and under medication for hyperuricemia or gout, in four Japanese 5 
communities. Cox proportional hazards models were used to estimate sex-specific hazard ratios 6 
of stroke and its types in relation to serum uric acid levels. During a median follow-up of 23.1 7 
years, we determined 1018 (488 men and 530 women) incident stroke, including 222 (99 and 8 
123) intraparenchymal hemorrhages, 113 (33 and 80) subarachnoid hemorrhages and 667 (347 9 
and 320) ischemic strokes. After adjustment for age, community and known cardiovascular 10 
risk factors, the multivariable hazard ratios (95%CIs) for the highest versus lowest quintiles of 11 
serum uric acid were 1.45 (1.07–1.96) for total stroke, 1.20 (0.65–2.20) for intraparenchymal 12 
hemorrhage, 1.46 (0.69–3.09) for subarachnoid hemorrhage and 1.61 (1.07–2.41) for ischemic 13 
stroke in women. The corresponding multivariable hazard ratios (95%CIs) in men were 1.02 14 
(0.74–1.35), 0.83 (0.40–1.72), 1.19 (0.38–3.75) and 1.00 (0.70–1.41). Furthermore, those 15 
positive associations with risks of total and ischemic strokes in women were more evident in 16 
non-users of antihypertensive medication rather than the users. In conclusion, elevated serum 17 
uric acid levels are independent predictors for total stroke in women, but not in men. The 18 
positive association in women was mostly attributable to ischemic stroke, and more 19 
2 
 
pronounced among non-users or users of antihypertensive medication. 1 
Key words: stroke; stroke types; serum uric acid; follow-up study; epidemiology 2 
Introduction 3 
Uric acid is the end product of purine catabolism, and it is positively associated with known 4 
cardiovascular risk factors, e.g., obesity, dyslipidemia, impaired glucose tolerance, chronic 5 
kidney disease and hypertension.1–3 Elevated serum uric acid levels could stimulate the renin–6 
angiotensin system and restrain release of endothelial nitric oxide, contributing to pre–7 
glomerular arteriolosclerosis and increasing blood pressure.4–6 Furthermore, elevated serum 8 
uric acid levels were reported as indicators of oxidative stress due to its compensatory 9 
mechanism against oxidative stress resulted from atherosclerosis and aging.7 A recent meta-10 
analysis of 13 cohort studies showed that serum uric acid levels were positively associated with 11 
risk of stroke in both sexes, whereas this association trended to be nonlinear in men.8 European 12 
prospective cohort studies reported consistent results to support predictive roles of serum uric 13 
acid on risk of stroke,9–13 but findings from American14–15 and Asian cohort studies16–20 14 
remained controversial. 15 
Elevated serum uric acid levels are regularly observed among hypertensive patients with 16 
antihypertensive medication use, especially diuretic use.21 The Atherosclerosis Risk in 17 
Communities (ARIC) study found that serum uric acid levels were positively associated with 18 
risk of ischemic stroke in non-users of diuretic, but not in the users,15 suggests that diuretic-19 
3 
 
inducted elevated serum uric acid levels were not predictor of risk of ischemic stroke. Based 1 
on prior studies, we hypothesized that elevated serum uric acid levels are independent predictor 2 
of risk of stroke among general Japanese population, and these associations are mainly 3 
observed in subjects without antihypertensive medication use. 4 
 5 
Methods 6 
Study Population  7 
The present study is part of the Circulatory Risk in Communities Study (CIRCS), a prospective 8 
community-based study of cardiovascular disease among general Japanese population since 9 
1963.22, 23 The surveyed population included 5442 men and 8279 women aged 40–79 years 10 
who participated in annual health checkups with the examination of serum uric acid between 11 
1985 and 1994. The subjects were enrolled from four communities: Ikawa town (a rural 12 
community in Akita Prefecture in northwestern Japan), the Minami-Takayasu district in Yao 13 
City (a southwestern suburb in Osaka Prefecture), Noichi town (a rural community in Kochi 14 
Prefecture in southwestern Japan), and Kyowa town (a rural community in Ibaraki Prefecture 15 
in central Japan). The baseline surveys were conducted in 1985–1990, 1985–1994, 1985–1990 16 
and 1985–1991, respectively. After the exclusion of subjects who had a history of stroke or 17 
coronary heart disease (162 men and 92 women), and used medication for hyperuricemia or 18 
gout (45 men and 2 women) at baseline, 5235 men and 8185 women were eligible for this 19 
4 
 
analysis. Subjects were followed to determine the incident stroke and its types until the end of 1 
2010 for Noichi, 2011 for Kyowa, and 2013 for Ikawa and Yao. Informed consent was obtained 2 
from the community representatives rather than each subjects because the present study is a 3 
secondary use of existing data for public health practice on cardiovascular disease prevention 4 
in local communities. Ethical approval of the CIRCS study has been admitted by the Ethics 5 
Committee of the Osaka Center for Cancer and Cardiovascular Disease Prevention and of 6 
Osaka University. 7 
 8 
Ascertainment of Cases 9 
The previous CIRCS study has reported the details of endpoint determination.22, 23 Candidate 10 
cases of stroke were obtained from various information sources of death certificates, national 11 
insurance claims, annual household questionnaires, annual cardiovascular risk surveys, and 12 
reports by either local physicians, public health nurses, or health volunteers. To confirm the 13 
diagnosis, all living suspected stroke cases were phoned, visited or invited to take part in risk 14 
factor surveys, or alternatively, a medical history was obtained from their families. Furthermore, 15 
medical records in the local clinics and hospitals were reviewed. In the case of death, histories 16 
from families and/or attending physicians were obtained and medical records were reviewed. 17 
Stroke was defined as a focal neurological disorder which contained rapid in onset and lasted 18 
at least 24h or until death. Stroke subtypes were classified as intraparenchymal hemorrhage, 19 
5 
 
subarachnoid hemorrhage, and ischemic stroke (large-artery occlusive infarction, lacunar 1 
infarction or others) primarily by using CT or MRI,24 which were available for 93.8% of stroke 2 
cases. The same diagnostic criteria of incident stroke and its types were used in all communities 3 
throughout the whole study period. 4 
 5 
Baseline Examination  6 
For all subjects, blood samples were drawn in seated position, stored in plain, siliconized glass 7 
tubes, centrifuged and its sera was separated within 30 minutes. Blood test had two time 8 
changes in methodology and measurement instrument during the baseline on September 1, 9 
1986 and on July 22, 1993. Serum uric acid was firstly measured with the phosphotungstic acid 10 
method using SMA-6/60 automatic analyzer (Technicon, Tarrytown, NY, USA), then the 11 
uricase method using SMAC automatic analyzer (Technicon), and same method suing 12 
Autoanalyzer 7250 (Hitachi Medical Corp., Ibaraki, Japan). Serum glucose was measured with 13 
the cupric-neocuproine method using SMA-6/60, the hexokinase method using SMAC and the 14 
glucokinase method using Autoanalyzer 7250. The values of serum glucose (mmol/L) 15 
measured using the cupric-neocuproine method were adjusted by using a linear regression 16 
formula: serum glucose concentrations (mg/dL) × 0.0474 + 0.541. Serum creatinine was 17 
measured originally with the non-compensated kinetic Jaffe method using SMA-6/60, SMAC 18 
and Autoanalyzer 7250 on different periods, and converted to a contiguous value with the 19 
6 
 
enzymatic method by minus 0.2 mg/dL.25 These measurements were performed at the Osaka 1 
Medical Central for Cancer and Cardiovascular Disease, an international member of the US 2 
National Cholesterol Reference Method Laboratory Network (CRMLN).26, 27 3 
An interview was conducted by trained observers to ascertain the smoking status, number of 4 
cigarettes smoked per day, the usual weekly intake of alcohol evaluated by units of “go” (a 5 
traditional Japanese unit of volume corresponding to 23g of ethanol), and the use of medication 6 
for hypertension or diabetes mellitus. In women, menopausal status was ascertained and 7 
postmenopausal status was defined by the end of menstruation for more than 6 months. Height 8 
in stocking feet and weight in light clothing were measured during health checkups, and body 9 
mass index was calculated as weight (kg) divided by the square of height (m2). Systolic and 10 
diastolic blood pressure in right arm were measured using standard mercury 11 
sphygmomanometers.28 Diabetes mellitus was defined as a fasting glucose level of ≥7.0 12 
mmol/L, or a non-fasting glucose level of ≥11.1 mmol/L or use of medication for diabetes 13 
mellitus. Estimated glomerular filtration rate (eGFR) was calculated using a standardized 14 
formula from the Japan Society of Nephrology Chronic Kidney Disease Initiative Guidelines: 15 
eGFR (ml/min per 1.73m2) = 194 × (serum creatinine [enzyme method])−1.094 × (age)−0.287 × 16 





Statistical Analyses 1 
In view of the different levels of serum uric acid between men and women, sex-specific 2 
analyses were performed at the present study. Age- and community-adjusted mean values or 3 
the prevalence of baseline characteristics were compared according to quintiles of serum uric 4 
acid using the analyses of covariance. Cox proportional hazards models were used to calculate 5 
sex-specific hazard ratios with 95% confidence intervals (CIs) of stroke and its types according 6 
to quintiles of serum uric acid and 1 standard deviation (SD) increment of serum uric acid (1.3 7 
mg/dL in men and 1.0 mg/dL in women).   8 
The initial hazard ratio model was adjusted for age and community, while multivariable 9 
model added body mass index (sex-specific quartiles), cigarette smoking status (never, former, 10 
and current 1-19 or 20 cigarettes per day), alcohol intake status (never, former, and current < 11 
23, 23–45, ≥46 g ethanol per day), systolic blood pressure (mmHg), antihypertensive 12 
medication use (no or yes), atrial fibrillation (no or yes), serum total cholesterol (mmol/L), 13 
serum triglycerides (sex-specific quartiles), estimated glomerular filtration rate (sex-specific 14 
quartiles), and diabetes mellitus (no or yes), and menopausal status (pre- or post-menopause) 15 
in women. To assess whether antihypertensive medication-induced changes of serum uric acid 16 
modified these associations, we conducted a subgroup analysis and stratified subjects by using 17 
of antihypertensive medication or not.  18 
SAS System (version 9.4; SAS Inc, Cary, NC) was used in all statistical analyses. P values 19 
8 
 
<0.05 were defined as statistically significant with two-tailed statistical tests. 1 
Results 2 
Table 1 shows sex-specific, age- and community-adjusted mean values or the prevalence of 3 
known cardiovascular risk factors at baseline according to serum uric acid quintiles. Subjects 4 
with elevated serum uric acid levels were older in women but similar in men. In both sexes, 5 
serum uric acid levels were positively associated with body mass index, systolic and diastolic 6 
blood pressure, the prevalence of antihypertensive medication use, serum total cholesterol, 7 
triglyceride and ethanol intake, and inversely associated with estimated glomerular filtration 8 
rate. Serum uric acid levels were positively associated with the prevalence of postmenopausal 9 
status in women. In addition, serum uric acid levels were positively associated with the 10 
prevalence of current smokers in women, but inversely in men. Subjects with higher serum uric 11 
acid levels had the higher prevalence of atrial fibrillation and the lower prevalence of diabetes 12 
mellitus in men, but the similar prevalence of them in women.  13 
During the median 23.1 years follow-up totaling 275,535 person-years, 1018 (488 men and 14 
530 women) cases of incident stroke, which included 222 (99 men and 123 women) 15 
intraparenchymal hemorrhages, 113 (33 men and 80 women) subarachnoid hemorrhages and 16 
667 (347 men and 320 women) ischemic strokes, were documented. 17 
Table 2 lists sex-specific, age- and community-adjusted and multivariable hazard ratios of 18 
total stroke, intraparenchymal hemorrhage, subarachnoid hemorrhage and ischemic stroke 19 
9 
 
according to serum uric acid quintiles. After adjustment for age, community and main 1 
cardiovascular risk factors, the multivariable hazard ratios (95%CIs) of total stroke for the 2 
highest versus lowest quintile of serum uric acid was 1.02 (0.74–1.35), P for trend = 0.89 in 3 
men and 1.45 (1.07–1.96), P for trend = 0.007 in women. The multivariable hazard ratios 4 
(95%CIs) of total stroke for 1 SD increment of serum uric acid was 1.02 (0.92–1.13) in men 5 
and 1.12 (1.03–1.22) in women. The positive association was confined to women, and the sex 6 
interaction was statistically significance (P for interaction < 0.05). When stratified by age, the 7 
association with risk of total stroke in women did not vary; the multivariable hazard ratios 8 
(95%CIs) for 1 SD increment of serum uric acid was 1.17 (0.99-1.38) for ages of 40–54 years, 9 
and 1.12 (1.01-1.25) for ages of 55–79 years (data not shown in Table). In women, serum uric 10 
acid levels were positively associated with risk of ischemic stroke, but not of intraparenchymal 11 
hemorrhage or subarachnoid hemorrhage. The multivariable hazard ratios (95%CIs) of 12 
ischemic stroke, intraparenchymal hemorrhage and subarachnoid hemorrhage stroke for the 13 
highest versus lowest quintiles of serum uric acid were 1.61 (1.07–2.41); P for trend = 0.07, 14 
1.20 (0.65–2.20); P for trend = 0.18 and 1.46 (0.69–3.09); P for trend = 0.15, respectively. In 15 
men, no positive associations were observed and the corresponding multivariable hazard ratios 16 
(95%CIs) were 1.00 (0.70–1.41); P for trend = 0.94, 0.83 (0.40–1.72); P for trend = 0.83 and 17 
1.19 (0.38–3.75); P for trend = 0.27.  18 
We next conducted a subgroup analysis, stratified by use of antihypertensive medication or 19 
10 
 
not, and the results are summarized in Table 3. In women, serum uric acid levels were 1 
positively associated with risk of total and ischemic strokes in non-users of antihypertensive 2 
medication, but not in the users, although the interaction with antihypertensive medication was 3 
not statistically significant (P for interaction = 0.87); the multivariable hazard ratios (95%CIs) 4 
for the highest versus lowest quintiles of serum uric acid was 1.46 (1.02–2.09); P for trend = 5 
0.02 for total stroke, and 1.62 (1.00–2.63); P for trend = 0.12 for ischemic stroke in non-users 6 
of antihypertensive medication. The multivariable hazard ratios (95%CIs) for 1 SD increment 7 
of serum uric acid was 1.11 (1.00–1.24) for total stroke, and 1.06 (0.91–1.22) for ischemic 8 
stroke in non-users of antihypertensive medication. In men, no positive associations with the 9 
highest versus lowest quintiles of serum uric acid or 1 SD increment of serum uric acid were 10 
observed for total or ischemic stroke in either non-users or users of antihypertensive medication.  11 
 12 
Discussion 13 
In this prospective community-based study of 5235 men and 8185 women aged 40–79 years, 14 
we found that serum uric acid levels were positively associated with risk of total stroke in 15 
women, but not in men. The positive association in women was mostly attributable to ischemic 16 
stroke, and more pronounced among non-users or users of antihypertensive medication. 17 
A recent meta-analysis of 12 prospective cohort and 1 nested case‐control studies showed 18 
the positive associations of serum uric acid with risk of stroke in both sexes; the summary of 19 
relative risks (95% CIs) of stroke for a 1 mg/dL increment of serum uric acid were 1.10 (1.05–20 
11 
 
1.14) in men, and 1.11 (1.09–1.13) in women. In that meta-analysis, a dose-response 1 
association was found in women (P for nonlinear trend = 0.51). However, the association of 2 
serum uric acid with risk of stroke trended to be nonlinear in men (P for nonlinear trend < 3 
0.001), and the risk of stroke increased significantly and steeply when values of serum uric 4 
acid exceeded 6 mg/dL.8 5 
Although European perspective cohort studies consistently found the positive associations 6 
of serum uric acid levels with risk of stroke,9–13 findings from Asian studies remained 7 
inconsistent.16–20 The Chin‐Shan Community Cardiovascular Cohort Study of 1703 Taiwan 8 
men and 1899 women aged 35 years or older with 11-year follow-up reported that plasma uric 9 
acid was positively associated with risk of incident stroke; the multivariable hazard ratios 10 
(95%CIs) of 1 mg/dL increment of plasma uric acid were 1.13 (0.88–1.46) in men, and 1.32 11 
(1.00–1.73) in women.16 A 2-year follow-up study of 61,304 Japanese men and 94,018 women 12 
aged 40–73 years reported J-shaped associations of serum uric acid levels with risk of self-13 
reported non-fatal stroke; the multivariable odds ratios (95%CIs) for the highest (≥7.1 mg/dL 14 
in men and ≥5.5 mg/dL in women) versus third quintiles (5.7–6.2 mg/dL in men and 4.4–4.8 15 
mg/dL in women) of serum uric acid was 1.26 (1.04–1.54) in men, and 1.24 (1.00–1.48) in 16 
women.17 However, the NIPPON DATA 80 study of 3596 Japanese men and 4576 women 17 
aged 30 years or older with 14-year follow-up and the Evidence for Cardiovascular Prevention 18 
from Observational Cohorts in Japan (EPOCH-JAPAN) Study of 15,628 Japanese men and 19 
12 
 
20,685 women aged 35–89 years with 441,771 person-years of follow-up reported that serum 1 
uric acid levels were not associated with risk of stroke mortality in either sex.18, 19 Another 9-2 
year follow-up study of 22,698 Korean men aged 30–77 years reported no association with risk 3 
of stroke mortality.20 4 
These associations of serum uric acid levels with risk of stroke trended to be non-linear. The 5 
NIPPON DATA 80 study reported the multivariable hazard ratios (95%CIs) of total stroke for 6 
each quartiles of serum uric acid were 0.84 (0.45-1.59), 0.66 (0.33-1.33) and 1.71 (0.92-3.17) 7 
in men, and 1.40 (0.54-3.63), 0.95 (0.37-2.45) and 1.12 (0.46-2.74) in women, respectively.18 8 
The EPOCH-JAPAN study reported the corresponding multivariable hazard ratios (95%CIs) 9 
for each quintiles of serum uric acid were 0.83 (0.58-1.18), 0.77 (0.52-1.13), 0.77 (0.52-1.13) 10 
and 1.19 (0.84-1.68) in men, and 1.27 (0.90-2.01), 0.98 (0.62-1.54), 1.05 (0.67-1.64) and 1.46 11 
(0.98-2.19) in women.19 Men had higher serum uric acid levels than women, even than 12 
postmenopausal women. The absence of association of serum uric acid levels with risk of 13 
stroke in the present study in men could be due to the antioxidant effect of serum uric acid. 14 
Furthermore, our study found J-shaped associations with risks of subarachnoid hemorrhage 15 
and ischemic stroke in men, and intraparenchymal and subarachnoid hemorrhage in women, 16 
which could be influenced in part by the antioxidant effect.  17 
Antihypertensive medication, such as diuretic, β-blocker, angiotensin converting enzyme 18 
inhibitor and non-losartan angiotensin II receptor blocker have an effect of increasing blood 19 
13 
 
uric acid concentrations, while other medication, such as calcium channel blocker and losartan, 1 
have an opposite effect in hypertensive patients.21 The Atherosclerosis Risk in Communities 2 
(ARIC) study of 13,413 American men and women aged 45–64 years with a 12.6-year follow-3 
up reported a positive association of serum uric acid levels with risk of ischemic stroke in non-4 
users of diuretic, but not in the users; the multivariable hazard ratios (95%CIs) of ischemic 5 
stroke for the highest (≥6.9 mg/dL) versus lowest quartile (≤4.8 mg/dL) of serum uric acid 6 
were 1.49 (1.00–2.23) in non-users of diuretic, and 0.73 (0.40–1.34) in the users.15 In Japan 7 
during the 1980s, calcium channel blocker and angiotensin converting enzyme inhibitor were 8 
approved by the Ministry of Health, Labour and Welfare, and selected as first choice drugs of 9 
hypertension treatment.30 Those drugs were likely to induce decreased or elevated serum uric 10 
acid levels and could weak the association of serum uric acid levels with risk of stroke. 11 
The potential mechanisms underlying the positive association of elevated uric acid levels 12 
with risk of stroke remains uncertain, although several possibilities have been proposed. First, 13 
elevated uric acid levels were associated with increased mean platelet volume,31 vascular 14 
endothelial function,32 vascular smooth muscle cell proliferation and inflammation,33 thereby 15 
increasing the risk of ischemic stroke. Second, uric acid-induced microvascular injury, e.g., 16 
vascular smooth muscle cell proliferation, could lead to pre-glomerular vascular disease and 17 
elevated blood pressure.4–6 Animal studies found that once microvascular injury occurred, 18 
hypertension turned to salt-driven and was independent of uric acid,34 while uric acid continued 19 
14 
 
to cause pre-glomerular vascular disease even under diuretic treatment.35 These findings 1 
suggested that uric acid-induced microvascular disease other than hypertension may account 2 
for the increased risk of stroke. Third, uric acid has a powerful free radical scavenging capacity 3 
against oxidative stress.36 A nested case-control study of 150 cases with elevated carotid 4 
intimal-medial thickness and 150 age-sex-matched controls within the ARIC study cohort 5 
showed that atherosclerosis cases had higher oxygen radical absorbance capacities than 6 
controls, and this difference was explained mostly by higher serum uric acid levels.7 Such a 7 
protective effect might mark the positive association of serum uric acid levels with risk of 8 
stroke in men partly due to the higher serum uric acid levels compared to those in women. 9 
As for strengths of our study, we used incident cases of stroke and its types as the target 10 
endpoint because serum uric acid may be more directly associated with it rather than fatal 11 
outcome. In addition, we analyzed these associations stratified by antihypertensive medication 12 
use or not, which allowed us to investigate these sex-specific associations among subjects with 13 
pharmacologically inducted hyperuricemia.  14 
Our study has several potential limitations. The single measurement of serum uric acid at 15 
baseline would make the association bias toward to null due to the random measurement 16 
variations. Therefore, the real association would be greater than that we reported. We have no 17 
data of use of diuretic or other type-specific antihypertensive medication, so we could not 18 
investigate the impact of medication-induced elevated or decreased serum uric acid levels on 19 
15 
 
risk of stroke.  1 
In conclusion, elevated serum uric acid levels are independent predictors for total stroke in 2 
women, but not in men of general Japanese population. The positive association in women was 3 
mostly attributable to ischemic stroke, and more pronounced among non-users or users of 4 
antihypertensive medication. 5 
 6 
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Table 1. Baseline characteristics of subjects according to quintiles of serum uric acid.  
 Serum uric acid quintiles P for 
difference   Q1 (low) Q2 Q3 Q4 Q5 (high) 
Men       
 No. at risk 1062  1085  1107  930 1051   
  Range of serum uric acid, mg/dL 0.7–4.6 4.7–5.3 5.4–5.9 6.0–6.6 6.7–11.2  
  Median serum uric acid, mg/dL 4.1  5.0  5.6  6.3  7.2   
  Age, year 56.7 (0.3) 55.8 (0.3) 53.8 (0.3) 55.2 (0.3) 55.2 (0.3) <0.001 
  Body mass index, kg/m2 22.1 (0.1) 22.5 (0.1) 23.0 (0.1) 23.5 (0.1) 23.9 (0.1) <0.001 
  Systolic blood pressure, mmHg 131.4 (0.6) 131.7 (0.5) 133.3 (0.5) 135.3 (0.6) 137.8 (0.6) <0.001 
  Diastolic blood pressure, mmHg 79.5 (0.4) 80.8 (0.3) 81.6 (0.3) 83.3 (0.4) 85.2 (0.4) <0.001 
  Antihypertensive medication use, % 10.4  9.3  11.2  16.0  22.7  <0.001 
Atrial fibrillation, % 1.0 0.9 0.7 0.8 2.2  0.006 
  Serum total cholesterol, mmol/L 4.74 (0.03) 4.84 (0.03) 4.85 (0.03) 4.95 (0.03) 5.05 (0.03) <0.001 
  Triglyceride, mmol/L 1.50 (0.04) 1.61 (0.04) 1.74 (0.04) 1.90 (0.04) 2.21 (0.04) <0.001 
  eGFR, ml/min per 1.73 mm2 88.4 (0.5) 85.9 (0.5) 81.9 (0.5) 78.8 (0.6) 73.5 (0.5) <0.001 
  Diabetes mellitus, % 10.0 7.8  8.0  7.4  7.2  <0.001 
  Current smokers, % 65.6  65.9  60.2 53.1  56.1  <0.001 
  Ethanol intake, g/day 28.0 (0.9) 27.9 (0.8) 27.6 (0.8) 29.8 (0.9) 33.2 (0.9) <0.001 
       
Women       
  No. at risk 1699  1614  1638  1548  1686   
  Range of serum uric acid, mg/dL 0.7–3.5 3.6–4.0 4.1–4.5 4.6–5.1 5.2–10.3  
  Median serum uric acid, mg/dL 3.2  3.8  4.3  4.8  5.7   
  Age, year 51.4 (0.2) 52.8 (0.2) 54.1 (0.2) 56.2 (0.2) 58.8 (0.2) <0.001 
  Body mass index, kg/m2 22.4 (0.1) 22.8 (0.1) 23.3 (0.1) 23.7 (0.1) 24.8 (0.1) <0.001 
  Systolic blood pressure, mmHg 129.0 (0.4) 130.2 (0.4) 131.2 (0.4) 132.6 (0.4) 135.3 (0.4) <0.001 
  Diastolic blood pressure, mmHg 76.3 (0.3) 77.4 (0.3) 78.8 (0.3) 79.6 (0.3) 81.7 (0.3) <0.001 
  Antihypertensive medication use, % 8.6  11.4  13.1  15.1  28.2  <0.001 
Atrial fibrillation, % 0.5 0.6 0.3 0.2 0.4  0.54 
  Serum total cholesterol, mmol/L 5.00 (0.02) 5.12 (0.02) 5.18 (0.02) 5.28 (0.02) 5.45 (0.02) <0.001 
  Triglyceride, mmol/L 1.27 (0.02) 1.38 (0.02) 1.50 (0.02) 1.65 (0.03) 1.92 (0.03) <0.001 
  eGFR, ml/min per 1.73 mm2 94.7 (0.5) 88.1 (0.5) 85.5 (0.5) 82.2 (0.5) 75.7 (0.5) <0.001 
  Diabetes mellitus, % 4.9  3.9  4.8  4.4  4.6   0.63 
  Current smokers, % 6.0  8.6  7.9  8.3  11.3   0.03 
  Ethanol intake, g/day 1.1 (0.2) 1.0 (0.2) 1.4 (0.2) 1.8 (0.2) 1.7 (0.2)  0.006 
  Postmenopausal, % 58.8  61.7  63.6  66.2  68.2  <0.001 
Values were presented as means (standard errors) or proportions, adjusted for age and community.  
eGFR, estimated glomerular filtration rate. 
Table 2. Age–, community–adjusted and multivariable hazard ratios (HRs, 95%CIs) of total stroke and its types according to quintiles of serum uric acid. 
 Serum uric acid quintiles 
P for trend 1SD increment§ 
 Q1 (low) Q2 Q3 Q4 Q5 (high) 
Men      
  
No. at risk 1062 1085 1107 930 1051   
Person-years 19,919 21,252 22,034 17,857 19,799   
Total stroke        
  No. of events 96 102 91 97 102   
  Age- and community-adjusted HR (95%CI) 
 
1.00 1.03 (0.78–1.37) 1.00 (0.75–1.33) 1.22 (0.92–1.62) 1.22 (0.92–1.62) 0.08 1.10 (1.01–1.21) 
  Multivariable HR (95%CI) 1.00 1.03 (0.78–1.36) 0.95 (0.71–1.27) 1.10 (0.82–1.48) 1.02 (0.74–1.35) 0.89 1.02 (0.92–1.13) 
Intraparenchymal hemorrhage        
  No. of events 19 21 23 21 15   
  Age- and community-adjusted HR (95%CI) 1.00 1.07 (0.57–1.98) 1.24 (0.67–2.29) 1.36 (0.73–2.54) 0.91 (0.46–1.81) 0.92 0.99 (0.80–1.22) 
  Multivariable HR (95%CI) 1.00 1.06 (0.57–1.98) 1.23 (0.66–2.29) 1.26 (0.67–2.41) 0.83 (0.40–1.72) 0.83 0.95 (0.75–1.19) 
Subarachnoid hemorrhage        
  No. of events 7 4 5 10 7   
  Age- and community-adjusted HR (95%CI) 
 
1.00 0.52 (0.15–1.77) 0.63 (0.20–1.99) 1.59 (0.60–4.20) 1.03 (0.36–2.96) 0.40 1.17 (0.82–1.69) 
  Multivariable HR (95%CI) 1.00 
 
0.53 (0.15–1.83) 0.66 (0.20–2.13) 1.96 (0.70–5.47) 1.19 (0.38–3.75) 0.27 1.22 (0.83–1.80) 
 Ischemic stroke        
  No. of events 69 74 62 65 77   
  Age- and community-adjusted HR (95%CI) 
 
1.00 1.05 (0.76–1.46) 0.96 (0.68–1.36) 1.13 (0.80–1.59) 1.29 (0.93–1.80) 0.11 1.13 (1.01–1.26) 
  Multivariable HR (95%CI) 1.00 1.04 (0.74–1.45) 0.89 (0.63–1.26) 1.01 (0.71–1.44) 1.00 (0.70–1.41) 0.94 1.02 (0.91–1.15) 
        
Women        
 No. at risk 1699 1614 1638 1548 1686   
 Person-years 37,083 35,060 35,780 32,845 33,905   
 Total stroke        
  No. of events 75 80 105 104 166   
  Age- and community-adjusted HR (95%CI) 
 
1.00 1.05 (0.76–1.44) 1.24 (0.92–1.67) 1.20 (0.89–1.62) 1.61 (1.22–2.13) <0.001 1.17 (1.08–1.26) 
  Multivariable HR (95%CI) 1.00 1.02 (0.74–1.40) 1.20 (0.89–1.63) 1.15 (0.84–1.56) 1.45 (1.07–1.96) 0.007 1.12 (1.03–1.22) 
Intraparenchymal hemorrhage        
  No. of events 22 14 21 30 36   
  Age- and community-adjusted HR (95%CI) 
 
1.00 0.64 (0.33–1.26) 0.88 (0.48–1.60) 1.25 (0.71–2.18) 1.28 (0.74–2.20) 0.08 1.21 (1.03–1.42) 
  Multivariable HR (95%CI) 1.00 0.64 (0.32–1.25) 0.86 (0.47–1.59) 1.22 (0.68–2.18) 1.20 (0.65–2.20) 0.18 1.19 (0.99–1.42) 
Subarachnoid hemorrhage        
  No. of events 13 11 13 15 28   
  Age- and community-adjusted HR (95%CI) 
 
1.00 0.87 (0.39–1.94) 0.97 (0.45–2.09) 1.14 (0.54–2.42) 1.89 (0.96–3.73) 0.02 1.25 (1.01–1.54) 
  Multivariable HR (95%CI) 1.00 0.81 (0.36–1.81) 0.85 (0.39–1.86) 0.99 (0.45–2.15) 1.46 (0.69–3.09) 0.15 1.15 (0.90–1.45) 
 Ischemic stroke        
  No. of events 39 55 70 55 101   
  Age- and community-adjusted HR (95%CI) 1.00 1.36 (0.90–2.05) 1.54 (1.04–2.28) 1.16 (0.77–1.76) 1.77 (1.21–2.58) 0.008 1.11 (1.00–1.23) 
  Multivariable HR (95%CI) 1.00 1.33 (0.88–2.02) 1.52 (1.02–2.26) 1.12 (0.73–1.72) 1.61 (1.07–2.41) 0.07 1.06 (0.95–1.18) 
§1 SD increment of serum uric acid was 1.3 mg/dL in men and 1.0 mg/dL in women. 
Q1: 0.7–4.6 mg/dL, Q2: 4.7–5.3 mg/dL, Q3: 5.4–5.9 mg/dL, Q4:6.0–6.6 mg/dL, Q5: 6.7–11.2 mg/dL in men; Q1: 0.7–3.5 mg/dL, Q2: 3.6–4.0 mg/dL, Q3: 4.1–4.5 mg/dL, Q4: 4.6–5.1 
mg/dL, Q5: 5.2–10.3 mg/dL in women.         
Multivariable hazard ratio adjusted for age, community, body mass index, cigarette smoking status, alcohol intake status, systolic blood pressure, atrial fibrillation, serum total cholesterol, 
serum triglycerides, estimated glomerular filtration rate, diabetes mellitus, antihypertensive medication use, and in women, menopausal status. 
 
Table 3. Multivariable hazard ratios (HRs, 95%CIs) of total and ischemic strokes according to quintiles of serum uric acid, stratified by antihypertensive medication use or not. 
  Antihypertensive medication non-user    Antihypertensive medication user 
P for interaction¶ 
 
Serum uric acid quintiles P for 
trend 
1 SD increment§ 
 Serum uric acid quintiles P for 
trend 
1 SD increment§ 
Q1 (low) Q2 Q3 Q4 Q5 (high)   Q1 (low) Q2 Q3 Q4 Q5 (high) 
Men                 
No. of risk 932 976 1001 783 819    130 109 106 147 232    
Person-years 18,032 19,502 20,313 15,360 16,094    1,887 1,750 1,720 2,496 3,705    
Total stroke                 
No. of events 73 83 75 74 59    24 19 16 23 43    
Multivariable HR (95%CI) 1.00  1.09 (0.79-1.50) 1.03 (0.74-1.43) 1.22 (0.87-1.71) 0.93 (0.65-1.35) 0.97  1.01(0.90-1.12)  1.00  0.80 (0.43-1.52) 0.74 (0.38-1.48) 0.81 (0.45-1.48) 1.04 (0.60-1.79) 0.73  1.05 (0.87-1.29) 0.98  
Ischemic stroke                 
No. of events 54 60 50 46 41    16 14 12 19 36    
Multivariable HR (95%CI) 1.00  1.08 (0.74-1.56) 0.92 (0.62-1.37) 1.01 (0.68-1.52) 0.85 (0.55-1.31) 0.44 0.97 (0.85-1.11)  1.00  0.89 (0.41-1.91) 0.83 (0.38-1.80) 1.00 (0.50-2.01) 1.31 (0.69-2.46) 0.36  1.15 (0.92-1.43) 0.32 
                 
Women                 
No. of risk 1596 1456 1433 1298 1149    103 158 205 250 537    
Person-years 35,203 31,939 31,667 27,917 24,028    1,881 3,121 4,113 4,929 9,877    
Total stroke                 
No. of events 63 62 83 78 89    12 18 22 26 77    
Multivariable HR (95%CI)  1.00  1.00 (0.70-1.42) 1.30 (0.93-1.82) 1.17 (0.83-1.66) 1.46 (1.02-2.09) 0.02  1.11 (1.00-1.24)  1.00  0.96 (0.46-2.03) 0.86 (0.42-1.76) 0.87 (0.42-1.77) 1.23 (0.64-2.36) 0.16  1.15 (0.97-1.37) 0.87  
Ischemic stroke                 
No. of events 32 41 56 41 52    7 14 14 14 49    
Multivariable HR (95%CI)  1.00  1.28 (0.80-2.05) 1.74 (1.12-2.70) 1.16 (0.72-1.88) 1.62 (1.00-2.63) 0.12  1.06 (0.91-1.22)  1.00  1.49 (0.59-3.80) 1.05 (0.41-2.67) 0.88 (0.34-2.29) 1.55 (0.66-3.65) 0.23  1.09 (0.87-1.35) 0.95  
§1 SD increment of serum uric acid was 1.2 mg/dL in men and 1.0 mg/dL in women of antihypertensive medication non-user, and 1.5 mg/dL in men and 1.2 mg/dL in women of antihypertensive medication user. 
¶The P value means an interaction of antihypertensive medication use and serum uric acid levels on risk of each event. 
Q1: 0.7–4.6 mg/dL, Q2: 4.7–5.3 mg/dL, Q3: 5.4–5.9 mg/dL, Q4:6.0–6.6 mg/dL, Q5: 6.7–11.2 mg/dL in men; Q1: 0.7–3.5 mg/dL, Q2: 3.6–4.0 mg/dL, Q3: 4.4–4.5 mg/dL, Q4: 4.6–5.1 mg/dL, Q5: 5.2–10.3 mg/dL in women.  
Multivariable hazard ratio adjusted for age, community, body mass index, cigarette smoking status, alcohol intake status, systolic blood pressure, atrial fibrillation, serum total cholesterol, serum triglycerides, estimated glomerular filtration rate (eGFR), diabetes mellitus and in women, menopausal status. 
 
